retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports Retatrutide 10mg Triple Agonist |

They were found to have significant HbA1c, and weight reduction compared to placebo in patients with diabetes and obesity respectively

A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes

So GLP-1 therapy reduces insulin secretion and levels, which have implications for the understanding of the mechanisms behind its effect on weight loss

The medication can open the door, but daily habits are what help you keep walking through it

Thus, less frequent and smaller meals are recommended, which would predispose patients to biliary sludge, gallstone formation and slowed biliary motility